SEOUL, South Korea, Jan. 8, 2026 -- STARMED, a pioneer in innovative minimally invasive treatment solutions, has announced a comprehensive rebranding. Now in its seventeenth year of operation, the company is formally transitioning from a Radiofrequency Ablation (RFA) specialist into a global multi-modality medical technology platform. Established in 2009, STARMED pioneered the first thyroid-dedicated RFA electrode, effectively creating a clinical field that did not previously exist. This technology has since been adopted into various international clinical guidelines and continues to m
- 'CART,' the blood pressure ring, recognized in Europe for its advanced vital sign monitoring technology- Targeting the global healthcare market beyond Europe through CE-MDR certification SEOUL, South Korea, Jan. 8, 2026 -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 8th that its ring-type blood pressure monitor, 'CART PLATFORM,' recently obtained the European Union's Medical Device Regulation (CE-MDR) certification. This certification was granted for the entire 'CART PLATFORM,' centered on the ring-type medical device equipped with photoplethysmography (
Proving global competitiveness in beauty tech by capturing the CES "Best of Innovation Award" AI-powered 'Scar Beauty Device' earns double honors in Beauty Tech and Digital Health categories LAS VEGAS, Jan. 7, 2026 -- Kolmar Korea announced that its AI-powered Scar Beauty Device has won the Best of Innovation Award in the Beauty Tech category at CES 2026, the world's largest consumer electronics and IT exhibition. The device also received an Innovation Award in the Digital Health category, achieving a double win at this year's CES. The Best of I
[ 메디채널 김갑성 기자 ] Proven Aerospace Industry Executive to Execute Next Phase of Strategic Growth Plan TULSA, Okla., Jan. 7, 2026 -- Accurus Aerospace Holdings, LLC ("Accurus"), a leading supplier of highly engineered structural parts, complex assemblies and electromechanical subsystems to the global aerospace, defense and space industry which operates through the "Accurus" and "Ferra" brand names, announced today the appointment of Daniel E. Murphy as President and Chief Executive Officer. Accurus is a portfolio company of Liberty Hall Capital Partners (&qu
LONDON, Jan. 7, 2026 -- UK-based skincare, aesthetic and medical device innovator iSMART Developments has announced a strategic partnership with L'Oréal Groupe, marking a significant milestone in the company's long-term growth and leadership within the professional grade light therapy industry. The partnership brings together iSMART's advanced LED engineering, innovation and regulatory expertise with L'Oréal Groupe's global scale, scientific infrastructure and commitment to cutting-edge skincare. Developed in partnership with L'Oréal, iSMART have cr
Leaders from Airbus Defence & Space and ST Engineering to Deliver Keynotes at Space Summit 2026 SINGAPORE, Jan. 7, 2026 -- Organised by Experia Events, Space Summit 2026 in Singapore (2–3 February) will serve as the primary staging ground for international industry leaders and space chiefs to define the next era of orbital commerce as the commercialisation of space technology gathers pace. The Summit arrives at a critical inflection point. The rapid growth of satellite constellations driven by lower launch costs and more mature space technologies is pus
[ 메디채널 김갑성 기자 ] - 동급 최초 신종 HLA-G 표적 엑소좀 약물 전달 플랫폼용 엑소좀 임상 cGMP 제조 싱가포르 2026년 1월 7일 -- JTC 런치패드 싱가포르(LaunchPad Singapore)에 본사를 둔 수직 통합 세포 유래물 CRDMO인 에스코 애스터(Esco Aster)가 샤인온 바이오메디컬(Shine-On Biomedical)의 HLA-G 표적 엑소좀 프로그램에 CMC 제조를 지원한다고 발표했다. 샤인온 바이오메디컬은 2023년에 에스코 애스터의 cGMP 서비스를 후원한 바 있다. 그 시작은 에스코 애스터의 세포주 플랫폼을 이용한 고수율 엑소좀 개발이었다. 공정, 분석 및 제형 개발, 엑소좀 약물 로딩, GMP 엔지니어링 실행, 안정성 연구에 관한 기술 보고서들이 샤인온의 IND 제출을 뒷받침했다. 이 IND는 2025년 1분기에 미국 FDA 승인을 받았다. 에스코 애스터는 또 샤인온의 지시에 따라 엑소좀 로딩 타당성 조사를 위한 기술 서비스도 제공하고 있다. 샤인온 바이오메디컬은 엑소좀 기반 약물 전달 분야에서 떠오르는 혁신 기업이다. 샤인온에서 독자 개발한 HLA-G 표적 엑소좀
선도적인 스위스 의료 기술 서비스 및 유통 기업인 헬스케어 홀딩 슈바이츠(Healthcare Holding Schweiz AG)가 메드베이스 인터내셔널(Medddbase International AG)의 과반수 지분을 인수하며 사업 포트폴리오를 확장했다. 메드베이스 인터내셔널은 산하에 메드베이스 슈바이츠(Medddbase Schweiz AG)와 메드베이스 도이칠란드(Medddbase Deutschland GmbH)를 두고 있다. 헬스케어 홀딩 슈바이츠의 경영은 윈터버그 어드바이저리(Winterberg Advisory GmbH)와 KKA 파트너스(KKA Partners)가 맡고 있다. 바르, 스위스, 2026년 1월 7일 -- 헬스케어 홀딩 슈바이츠가 장크트갈렌 부크스에 본사를 둔 메드베이스 인터내셔널의 경영권 지분을 성공적으로 인수했다. 메드베이스는 스위스와 유럽연합(EU), 영국 전역에서 고도로 전문화된 의료 제품 상용화 및 물류 서비스를 제공하는 기업이다. 지난 20년 가까이 5개 거점(협력사 포함)을 기반으로 50개 이상의 글로벌 의료 기술 제조사를 전담 지원해 왔으며, 연간 50만 건에 육박하는 제품 배송을 처리하고 있다.
PISCATAWAY, N.J., Jan. 6, 2026 -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, scheduled for January 14, 2026, at the San Francisco Marriott Marquis, with both in-person and virtual attendance options available. Now in its fifth year, GenScript Biotech Global Forum has become a convening platform to push the boundaries of what's possible for the global biotech ecosystem. Held alongside the annual J.P. Morgan Healthcare Conference week, the Forum brings together the s
Healthcare Holding Schweiz AG, a leading service provider and distributor of medical technology in Switzerland, expands its portfolio through the acquisition of a majority stake in Medddbase International AG, which includes Medddbase Schweiz AG and Medddbase Deutschland GmbH. Healthcare Holding Schweiz is managed by Winterberg Advisory GmbH and KKA Partners. BAAR, Switzerland, Jan. 6, 2026 -- Healthcare Holding Schweiz AG has successfully acquired a majority interest in Medddbase International AG, headquartered in Buchs, St. Gallen. Medddbase is a highly specialized service pro